Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma[1], [2]. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news